Bacterial infections are commonly treated with antimicrobials, but the rise of multi-drug resistance and the presence of biofilms can compromise treatment efficacy. Recently, new approaches using live bacteria or engineered microorganisms have gained attention in the fight against several diseases. In their recent work, Lluch-Senar and colleagues (Garrido et al, 2021) genetically modified the lung pathogen Mycoplasma pneumoniae to attenuate its virulence and secrete antibiofilm and bactericidal enzymes. Their strategy successfully altered a Staphylococcus aureus biofilm on catheters implanted in mice, providing an additional demonstration of the potential of genetically engineered microorganisms as therapeutic agents.

Mol Syst Biol. (2021) 17: e10574
See also: V Garrido et al (October 2021)

Biofilms are composed of microorganisms embedded within a complex extracellular matrix. This structure provides a physical barrier protecting microbes from desiccation and other stresses. For example, antibiotic susceptibility of bacterial populations contained within a biofilm is considerably decreased, often by up to 1,000-fold (Heiby et al, 2010). Biofilms are commonly found on medical devices such as catheters and are notoriously difficult to eliminate, which can result in infections. Given the lack of efficient solutions to dissolve biofilms, combined with the steady rise in antibiotic resistance worldwide, new strategies must be developed to maintain the ability to prevent or treat infections.

During the past decades, most drugs consisted of molecules displaying pharmacological activities. Different levels of drug complexity are possible ranging, for example, from simple antibiotic molecules such as penicillin to proteins such as insulin or monoclonal antibodies. But what if we could use live organisms as drugs? Bacteriophages can be used to treat infections (Fathima & Archer, 2021), and probiotics are already well known to the general public. These natural organisms can have beneficial effects, but their impact on health or disease often remains limited. Could we instead rationally design microorganisms to prevent or treat specific diseases? This idea is particularly attractive given the remarkable progress of synthetic biology. In principle, engineered organisms also offer countless possibilities.

Medicines composed of living cells are generally referred to as live biotherapeutics products (LBPs) (Pot & Vandenplas, 2021). Several academic and industrial laboratories worldwide are engineering LBPs. The cell chassis usually consists of well-established laboratory workhorses such as Escherichia coli or Lactococcus sp. (Aggarwal et al, 2020), largely due to the wealth of data and robust methods developed for these bacterial species. However, many less conventional organisms could be better suited for certain indications or present other advantages. Surprisingly, few people are aware that the lung pathogen Mycoplasma pneumoniae is one of the best-studied microorganisms. For the past 15 years, an impressive amount of work was performed on this wall-less bacterium, resulting in a detailed cellular description (Güell et al, 2009; Kühner et al, 2009; Yus et al, 2009; Trussart et al, 2017). More recently, the genetic engineering toolbox available for M. pneumoniae was expanded to considerably facilitate genome modifications, enabling a new level of studies with this near-minimal bacterium (Piñero-Lambea et al, 2020).

In their recent study, Lluch-Senar and colleagues (Garrido et al, 2021) performed the first engineering and evaluation of M. pneumoniae as an LBP chassis (Fig 1). They first investigated the impact of selected gene deletions to attenuate this pathogen based on data from the literature, and tested the resulting strains using a mouse mastitis model of infection. Two genes, mpn133 and mpn372, were removed to obtain a fully attenuated cell chassis called CV2. The team next identified signal peptides and assessed different promoters to allow efficient protein secretion. The signal peptide from gene mpn142 was found to provide the best results and was further optimized to remove secondary structures from its mRNA counterpart. A genetic module allowing the secretion of dispersin B was then introduced in the CV2 strain to create an LBP capable of degrading Staphylococcus aureus biofilms. Surprisingly, this derivative of the CV2 strain was clearly surpassed by the wild-type M. pneumoniae secreting dispersin B in vivo but not in vitro or ex vivo. This result suggested that the attenuation of the strain impaired its activity in mice and that additional factors such as inflammation could be important to eliminate S. aureus biofilms in vivo. Faced with this situation, the authors inserted another genetic module, this time expressing the glycyglycine endopeptidase lysostaphin that attacks the S. aureus cell wall. The CV2 strain secreting dispersin B and lysostaphin showed improved activity although with more variability than the wild-type strain producing dispersin B.

Overall, the work conducted by Lluch-Senar and colleagues is promising. Importantly,
several relevant conclusions can be drawn from their experiments. First, alternative model organisms, such as *M. pneumoniae*, deserve to be considered in LBP design. The lack of a cell wall in *M. pneumoniae* facilitates the secretion of bioactive compounds and the production of molecules targeting bacterial peptidoglycans. Second, knowledge is key for rational engineering. Having access to solid data from the literature and validating hypotheses in vivo is crucial. Surprises related to the engineered organism behavior are likely, particularly if some initial information used for the design comes from different sources or contexts. For instance, virulence genes in *M. pneumoniae* were identified for lung infection, while the CV2 strain was evaluated in a mouse mastitis model and finally used to degrade biofilms on catheters inserted subcutaneously. Third, reassessment and iterative strain improvement will likely be needed to reach the desired efficacy. Finally, strict biocontainment measures will certainly be required by regulatory agencies and for the acceptance of LBPs by the public. Minimizing the risk of infection in other organs and avoiding dissemination to other patients or in the environment is an obvious condition for clinical use.

With the advances in synthetic biology and in the engineering of LBPs, several applications are expected to be developed in the coming years. We are only witnessing the beginning of this exciting field that has the potential to prevent or treat a wide variety of diseases such as multi-drug-resistant infections and even cancer. LBPs could provide new therapeutic avenues where conventional drugs have failed or reached their limits.

References

Aggarwal N, Breeden AME, Davis CM, Hwang IY, Chang MW (2020) Engineering probiotics for therapeutic applications: recent examples and translational outlook. *Curr Opin Biotechnol* 65: 171 – 179

Fathima B, Archer AC (2021) Bacteriophage therapy: recent developments and applications of a renaissant weapon. *Res Microbiol* 105863
Garrido V, Piñero-Lambea C, Rodriguez-Arce I, Paetzold B, Ferrar T, Weber M, García-Ramallo E, Gallo C, Collantes M, Peñuelas I et al (2021) Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo. Mol Syst Biol 17: e10145

Guell M, van Noort V, Yus E, Chen W-H, Leigh-Bell J, Michalodimitrakis K, Yamada T, Arumugam M, Doerks T, Kühner S et al (2009) Transcriptome complexity in a genome-reduced bacterium. Science 326: 1268 –1271

Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322 – 332

Kühner S, van Noort V, Betts MJ, Leo-Macias A, Batisse C, Rode M, Yamada T, Maier T, Bader S, Beltran-Alvarez P et al (2009) Proteome organization in a genome-reduced bacterium. Science 326: 1235 –1240

Piñero-Lambea C, Garcia-Ramallo E, Martinez S, Delgado J, Serrano L, Lluch-Senar M (2020) Mycoplasma pneumoniae genome editing based on oligo recombineering and Cas9-mediated counterselection. ACS Synth Biol 9: 1693 –1704

Pot B, Vandenplas Y (2021) Factors that influence clinical efficacy of live biotherapeutic products. Eur J Med Res 26: 40

Trussart M, Yus E, Martinez S, Baü D, Tahara YO, Pengo T, Widjaja M, Kretschmer S, Swoger J, Djordjevic S et al (2017) Defined chromosome structure in the genome-reduced bacterium Mycoplasma pneumoniae. Nat Commun 8: 14665

Yus E, Maier T, Michalodimitrakis K, van Noort V, Yamada T, Chen W-H, Wodke JAH, Guell M, Martinez S, Bourgeois R et al (2009) Impact of genome reduction on bacterial metabolism and its regulation. Science 326: 1263 –1268

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.